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Abstract
The outcome for patients with advanced metastatic and recurrent prostate cancer is still poor. Therefore, new
chemotherapeutics are required, especially for killing cancer stem cells that are thought to be responsible for disease
recurrence. In this study, we screened the effect of a novel palladium-based anticancer agent (Pd complex) against six
different prostate cancer cell lines, and primary cultures from seven Gleason 6/7 prostate cancer, three Gleason 8/9 prostate
cancer and four benign prostate hyperplasia patient samples, as well as cancer stem cells selected from primary cultures.
MTT and ATP viability assays were used to assess cell growth and flow cytometry to assess cell cycle status. In addition,
immunofluorescence was used to detect cH2AX nuclear foci, indicative of DNA damage, and Western blotting to assess the
induction of apoptosis and autophagy. The Pd complex showed a powerful growth-inhibitory effect against both cell lines
and primary cultures. More importantly, it successfully reduced the viability of cancer stem cells as first reported in this
study. The Pd complex induced DNA damage and differentially induced evidence of cell death, as well as autophagy. In
conclusion, this novel agent may be promising for use against the bulk of the tumour cell population as well as the prostate
cancer stem cells, which are thought to be responsible for the resistance of metastatic prostate cancer to chemotherapy.
This study also indicates that the combined use of the Pd complex with an autophagy modulator may be a more promising
approach to treat prostate cancer. In addition, the differential effects observed between cell lines and primary cells
emphasise the importance of the model used to test novel drugs including its genetic background, and indeed the
necessity of using cells cultured from patient samples.
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Introduction
Prostate cancer is the most commonly diagnosed cancer in
males and is the second highest cause of male cancer-related death
[1,2]. Although new drugs have recently been introduced into the
clinic, the response to therapy for metastatic prostate cancer is still
poor [3,4,5]. Therefore, there is an urgent need for more efficient
or different kinds of drugs specifically targeting radio-recurrent
and hormone-resistant prostate cancer, as well as prostate cancer
stem cells (CSCs) [3,4,6]. New metal-based agents like palladium
(Pd) complexes are promising for the development of improved
chemotherapeutic drugs. There is a significant similarity between
the coordination chemistry of Pd and platinum (Pt) compounds as
antitumor drugs [7].
Although the synthesis of Pd complexes with anti-fungal, anti-
viral, anti-cancer, and anti-bacterial activities dates back to more
than 30 years [8], the anti-cancer activities of Pd complexes have
become of increasing interest within the last 15 years. As such,
different Pd complexes with promising activity against varying
kinds of tumor cell lines from both solid tumors and hematological
malignancies have been synthesized and tested over the years
[9,10,11,12,13,14,15]. Their lipophilicity or solubility seems to
provide satisfactory cytostatic activity [16]. The increased solubil-
ity of Pd complexes, compared to platinum, also makes Pd
complexes more attractive. For example, Pd complexes of
glyoxylic oxime were found to have higher aqueous solubility
than platinum(II) (Pt) complexes of glyoxylic oxime [17].
There are only a few studies on the effect of newly-synthesized
palladium(II) complexes on prostate-derived cell lines: for example,
palladium(II) has been complexed with different ligands such as
triazole [10], triphenylphosphines [18], dithiocarbamate [19], or
hydrazine [20]; and even curcumin, which is a well-known plant-
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based compound with apoptosis-inducing activity on cancer cells
[21].
In addition to the ligands above, the bioorganic and medicinal
chemistry of 2,29:69,20-terpyridine (terpy) complexes of Pd(II) and
Pt(II) is also an active and growing area of interest [13,22]. Taking
into account the promising activity of Pd complexes against
cancer, we have therefore synthesized new Pt and Pd complexes;
[Pd(sac)(terpy)](sac)?4 H2O, [Pt(sac)(terpy)](sac)?5 H2O, [PdCl(ter-
py)](sac)?2 H2O, [PtCl(terpy)](sac)?2 H2O (sac = saccharinate, and
terpy= 2,29:6920-terpyridine) [23]. Among these, the Pd complex-
es, but not the Pt complexes, were found to exhibit considerable
anti-growth effect against non-small cell lung cancer cells in vitro
[24]. The [Pd(sac)(terpy)](sac)?4 H2O complex was further inves-
tigated against breast cancer cells both in vitro and in vivo and
showed powerful anti-growth activity against this cancer type [25].
In the present paper, we have investigated the cytotoxic activity
of our formulation of Pd complex, formulated as [PdCl(terpy)](-
sac)?4 H2O, against prostate cancer cells. The Pd complex was
found to exhibit powerful growth-inhibiting activity, against cell
lines and primary cultures, as well as prostate CSCs. The
induction of apoptosis in cell lines by this compound indicates its
potential as a new cytotoxic agent. However, the induction of
autophagy but not apoptosis in primary prostate cells suggests that
a combination of the complex with autophagy inhibitors may be a
preferred treatment strategy. Significantly, we have shown a
differential effect of the compound, which is dependent on genetic
background of cells that could also influence treatment choice. In
addition, to our knowledge, this is the first study showing anti-
growth activity of the Pd complexes against CSCs and it thereby
warrants further investigation as a chemotherapeutic for prostate
cancer.
Methods
Culture of Cell Lines
In this study, six different prostate cell lines (PNT1A, PNT2-C2,
BPH-1, PC-3, LNCaP, P4E6) were used (Table 1). These cell lines
encompass the spectrum of cellular differentiation status (basal,
intermediate and luminal phenotypes), as well as the spectrum of
normal, early cancer and late cancer. BPH-1 is derived from
benign prostate hyperplasia (BPH), while PNT2-C2 and PNT1A
are derived from normal prostate. PC-3, LNCaP and P4E6 are
cancer cell lines. LNCaP, PNT2-C2, PNT1A were grown in
RPMI medium with 10% FCS (foetal calf serum); PC-3 was grown
in Ham’s F-12 medium with 7% FCS; BPH-1 was grown in RPMI
medium with 5% FCS; P4E6 was grown in KSFM (Keratinocyte
serum free medium) with 2% FCS. No antibiotics were used in any
media. The cells were incubated at 37uC in a humidified
atmosphere containing 5% CO2.
Culture of Primary Prostate Epithelial Cells
Primary prostate epithelial cells were isolated from human tissue
samples. The samples were collected with ethical permission from
York District Hospital (York, UK) and Castle Hill Hospital
(Cottingham, UK). Benign prostatic hyperplasia (BPH) and
prostate cancer samples were obtained from TURP (transurethral
resection of the prostate), radical prostatectomy (laparoscopic and
open) and cystectomy operations. All patients gave written consent
for their tissue to be used for research and all patient samples were
anonymised. Permission was approved by the Local Research
Ethical Committees, associated with York District Hospital and
Castle Hill Hospital. Permission was administered by the
Yorkshire and Humber Research Ethics Committee.
Prostate epithelial cells were cultured as previously described
[26] in stem cell media (SCM) consisting of keratinocyte serum-
free media (KSFM) with bovine pituitary extract (BPE) and
epidermal growth factor (EGF), glutamine, stem cell factor (SCF),
granulocyte macrophage colony stimulating factor (GM-CSF),
leukaemia inhibitory factor (LIF) and cholera toxin. Cells were
grown with STO feeder cells (irradiated at 60 Gy) on collagen I-
coated plates. The detailed information of the primary cells used is
given in Table 2.
Isolation of Cancer Stem Cells, Transit Amplifying Cells
and Committed Basal Cells
Epithelial cells from human tumour or BPH materials were
cultured for several weeks and the cells treated at very low
passages. The cultured basal cell population were trypsinized,
resuspended in SCM and then plated on BSA-blocked collagen I-
coated plates. After 30 min, cells that did not attach to the
substratum were collected, consisting of the committed basal cells
(CBs), which are a2b1integrinlo. The cells that attached to
substratum were trypsinised, resuspended in MACs buffer and
incubated with CD133-microbeads (Cat no. 130-050-801, Milte-
nyi Biotec Inc., Auburn, CA, USA). MACs MS columns (Cat
no. 130-042-201, Miltenyi Biotec Inc., Auburn, CA, USA) were
used to select the CD133+ and CD1332 cells. Finally, the three
cell populations were obtained: stem cells (SCs) - a2b1integrinhi/
CD133+, transit-amplifying cells (TAs) - a2b1integrinhi/CD1332
and committed basal cells (CBs) - a2b1integrinlo.
Chemicals
The palladium (Pd) complex was synthesized in the Chemistry
Department of the Science and Art Faculty of Uludag University.
The synthesis, characterization and crystal structure of the
palladium(II) complex has been reported elsewhere [23].
[PdCl(terpy)](sac)?2 H2O was synthesized by the direct addition
of an equimolar amount of sac ions to [Pd(terpy)Cl]Cl?2 H2O in
solution in high yield. The orange crystals of the compound were
obtained and its molecular structure was confirmed by X-ray
diffraction. The chemical structure is shown in Figure 1A. Stock
and final concentrations of the Pd complex were prepared in the
appropriate culture medium. The Pd complex was used at
concentrations ranging from 0.39 to 100 mM. Cisplatin
(sc200896, Santa Cruz Biotechnology, Santa Cruz, CA, USA)
(Figure 1B) and Etoposide (E1383, Sigma-Aldrich, Saint Louis,
MO, USA) (Figure 1C), were used as positive controls for cytotoxic
activity at doses of 25 mM and 12 mM or 6 mM, respectively.
MTS Assay
This assay was performed for the initial screening of the effect of
the Pd complex on the cell lines and the whole cell population of
primary cultures. The CellTiter 96H Aqueous One Solution Cell
Proliferation Assay kit (G3580, Promega, Madison, WI, USA) was
used and the manufacturer’s instructions were followed. Briefly,
after treating cells that were seeded at a density of 5,000 cells per
well in a 96-well plate in triplicate for a desired period (24 h, 48 h,
72 h), 20 mL of reagent was added to each well. Following 2.5 h
incubation at 37uC, the absorbance was read at 485 nm using a
plate reader (PolarStar Optima, BMG Labtech, UK). Percent
viability was calculated using the formula (% Viability = [(Sample
Absorbance/Control Absorbance)]6100.
ATP Assay
This assay was employed for the bioluminescent determination
of the adenosine 59-triphosphate (ATP) released from fractionated
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living cells (cancer stem cells, transit amplifying cells and
committed basal cells). As ATP is rapidly degraded in dead cells,
high intracellular levels provide a selective assay for living cells.
The ATP-bioluminescent somatic cell assay kit (FLASC, Sigma-
Aldrich, Saint Louis, MO, USA) was used with protocol
modifications. Briefly, 50–500 cells per well were seeded in a
collagen-coated 96 well plate in triplicate. After treating cells for
72 h, 150 mL of medium was removed from each well. 50 mL of
cell extraction reagent was added into each original well.
Following 20 min incubation at RT, 50 mL of cell extract was
transferred to a white 96-well plate. Finally, 50 mL of ATP assay
mix solution was added into the wells and luminescence was read
using a plate reader (PolarStar Optima, BMG Labtech, UK).
Percent viability was calculated using the formula (% Viabili-
ty = [(Sample RLU/Control RLU)]x100 where RLU refers to
relative light units.
Immunofluorescence
cH2AX staining: Cells were seeded onto 8-well collagen I-
coated chamber slides. Briefly, following 48 h treatment with the
Pd complex or etoposide, cells were washed with PBS and fixed
with 2% paraformaldehyde in PBS with 0.2% Triton X-100,
pH 8.2 for 20 min, and then permeabilised with 0.5% NP40 in
PBS for 20 min at RT followed by three washes with PBS. After
blocking of non-specific binding with 2% BSA in PBS with 1%
goat serum for 1 hour at RT, primary antibody (anti-phospho-
histone H2A.X (Ser139), clone JBW301, Millipore, Cat no. 05–
636) at 1:1000 dilution was added in 3% BSA in PBS at 4uC
overnight followed by three washes in 0.5% BSA in PBS with
0.175% Tween 20. Following incubation with secondary antibody
(Goat anti-mouse Alexa Fluor 568, Invitrogen, Cat no. A-11004)
at 1:1000 dilution for 45 min in 3% BSA in PBS and three more
washes in the same washing buffer, the slides were mounted using
Vectashield with DAPI (Vector Laboratories, Cat no. H-1200).
LC3-B staining: Cells were treated as above then fixed with 4%
paraformaldehyde, followed by an incubation in 0.3% Triton X-
100. After blocking with 10% normal goat serum, cells were
incubated in anti-LC3B 1:200 (Ab51520, abcam) diluted in 0.1%
Triton X-100 in PBS. Secondary antibody was Alexa Fluor
568 goat anti-rabbit IgG 1:1000 (Invitrogen A11011).
Flow Cytometry
Following drug treatment, floating cells in the media were
pooled with adherent cells, which were collected by trypsinisation.
Following centrifugation cells were resuspended in 0.5 ml PBS.
Cells were fixed in 2 ml ice cold 70% ethanol, which was added in
a dropwise fashion while vortexing. Cells were incubated on ice for
30 min then washed in 5 ml PBS and resuspended in 0.4 ml PBS.
Following storage at 4uC overnight, 50 ml of RNAse (1 mg/ml)
and 50 ml of propidium iodide (1 mg/ml) were added to the cells.
Following incubation at 37uC for 30 min the cells were analysed
for 2N and 4N DNA content on a flow cytometer (Cyan ADP
Analyser, Beckman Coulter).
Table 1. Cell lines.
Cell line Diagnosis Source/Reference
PNT1A Normal prostate epithelium immortalized with SV40 Kind gift to the lab of Norman Maitland from P. Berthon Currently
available from Health Protection Agency Culture Collections.
PNT2-C2 Normal prostate epithelium immortalized with SV40 Obtained from ECACC (no longer available from ECACC)
BPH-1 Primary epithelial culture from benign prostatic hyperplasia
immortalized with SV40
Obtained by Norman Maitland, with kind permission from Simon
Hayward [49]. Not commercially available.
P4E6 Epithelial culture established from well-differentiated prostate cancer/E6
gene from human papillomavirus introduced by retroviral insertion
Derived in York [50]. Currently available from Health Protection
Agency Culture Collections.
PC-3 Prostate adenocarcinoma/bone metastasis ATCC
LNCaP Prostate carcinoma/lymph node metastasis ATCC
doi:10.1371/journal.pone.0064278.t001
Table 2. Primary epithelial cells.
Sample Passage Operation Diagnosis
01409 6 C benign
03108 6 T benign
01608 2+3 T benign
08109 4 T benign
00409 4 T benign
07611 2 T benign
22612 3 T benign
05908 2 T benign
07011la 3 R Cancer on hormones Gleason 7
07011lb 3 R Cancer on hormones Gleason 7
05411rb 5 R Cancer Gleason 7
07311ra 3 R Cancer Gleason 7
06711rb 6 R Cancer Gleason 6
06211rb 4 R Cancer Gleason 7
06611lb 5 R Cancer Gleason 7
04811rb 5 R Cancer Gleason 6
06411ra 3 R Cancer Gleason 7
06411lb 3 R Cancer Gleason 7
25212ra 3 R Cancer Gleason 7
23912ra 6 R Cancer Gleason 9
22412 2/3 chT Cancer Gleason 7
22112 4 R Cancer Gleason 7
22012ra 5 R Cancer Gleason 7
07311la 7 R Cancer Gleason 7
16312 5 chT Cancer Gleason 8
22912 2 chT Cancer Gleason 8/9
14912 3 chT Cancer Gleason 9
C=Cystectomy/T = Transurethral resection of the prostate/R = Radical
Prostatectomy/chT = channel TURP.
doi:10.1371/journal.pone.0064278.t002
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Western Blotting
Following drug treatment, cell lysates were harvested using
Cytobuster Protein Extraction Reagent (71009, EMD Millipore,
Darmstadt, Germany) with protease inhibitors (cOmplete, EDTA-
free Protease Inhibitor Cocktail Tablets, Roche Applied Science,
UK). 20 mg of protein extract were loaded on 12% SDS-PAGE
gels and wet-transferred to a PVDF membrane. Antibodies used
include: monoclonal anti-b-actin 1:5000 (A5316, Sigma-Aldrich),
anti-LC3B 1:3000 (Ab51520, abcam), cleaved caspase-3 (Asp175)
1:1000 (9661S, Cell Signaling Technology) and secondary
antibodies were Rabbit anti-mouse-HRP 1:10000 (P0260, Dako)
and anti-rabbit IgG HRP-linked 1:5000 (Cell Signaling Technol-
ogy Inc. 7074S). Kaleidoscope protein marker was run on each gel
(161-0324, Bio-Rad).
Statistics and Calculations
MTS and ATP assays were performed in triplicate and data
presented as the mean +/2 standard deviation. IC50 values
(Table 3 and Table 4) were calculated from graphs of transformed
data following application of the nonlinear regression (curve fit)
that represents the log(inhibitor) ‘v’ normalized response (Graph-
Pad Prism software) (Supplementary Figures S1 and S2). For
significance calculations, the Wilcoxon rank sum test was used
(Sigmaplot). Flow cytometry analysis was carried out in triplicate
and results are presented as an average with error bars indicating
the standard error.
Results
Effect of Pd Complex on Cell Lines
The anti-growth effect of the Pd complex was tested against six
different cell lines at three different time points, 24 h, 48 h and
72 h (Figure 2). The Pd complex inhibited the growth of all cell
lines almost completely at 100 mM concentration at 72 h. A
comparison was made to etoposide (25 mM) and to cisplatin
(12 mM), used as known cytotoxic agents. At 72 h, the lowest IC50
value, 0.1399 mM, was for the BPH-1 cell line, with PNT1A cells
having a similarly low IC50 of 0.1064 mM, while PNT2-C2 cells
were more resistant, with an IC50 value of 0.9033 mM (Table 3).
The well differentiated early stage prostate cancer cell line P4E6,
and LNCaP, which is from a lymph node metastasis with the most
luminal phenotype (androgen-positive) had IC50s of 4.372 mM and
3.433 mM, respectively, whereas the cancer cell line from a bone
metastasis, PC-3, had an IC50 value of 26.79 mM. There was a less
dramatic effect on PNT2-C2 cells compared to the other normal
and benign cell lines (Figure 2A(iii)). However, the cancer cell line
from the bone metastasis is least susceptible to the drug, with a
significantly higher IC50 (Figure 2B(iii)). Overall, the Pd complex
successfully reduced viability of all cell lines tested with some
variation in response.
Effect of Pd Complex on Primary Cultures from Benign
and Malignant Samples
The most complete dose response was observed at the 72 h
time-point, and so this time point was used to explore the anti-
Figure 1. Chemical structures. (A) Palladium complex [PdCl(terpy)](sac)?2 H2O, (sac = saccharinate, and terpy = 2,29:69,20-terpyridine).
M= Palladium(II) (B) Cisplatin (C) Etoposide.
doi:10.1371/journal.pone.0064278.g001
Table 3. IC50 values of the Pd complex in cell lines.
Cell lines 24 h IC50 (mM) Cell lines 48 h IC50 (mM) Cell lines 72 h IC50 (mM)
PNT1A 27.97 PNT1A 1.258 PNT1A 0.1064
PNT2-C2 1.732 PNT2-C2 17.17 PNT2-C2 0.9033
BPH-1 17.62 BPH-1 1.881 BPH-1 0.1399
AVERAGE 15.774 AVERAGE 6.769666667 AVERAGE 0.3832
P4E6 21.80 P4E6 9.660 P4E6 4.372
PC-3 98.91 PC-3 49.15 PC-3 26.79
LNCaP 105.5 LNCaP 11.90 LNCaP 3.433
AVERAGE 75.40333333 AVERAGE 23.57 AVERAGE 11.53166667
doi:10.1371/journal.pone.0064278.t003
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growth effect of the Pd complex on primary cultures from patient
tissue to assess a model closer to the disease state. The Pd complex
was tested on primary cultures derived from patients with benign
prostate hyperplasia (BPH, n= 4 from four patients) (Figure 3A),
prostate carcinoma with low Gleason grades (6/7) (n = 9 from
seven patients) (Figure 3B) and with high Gleason grades (8/9)
(n = 3 from three patients) (Figure 3C). The dose response curve
was strikingly similar between BPH and Gleason 6/7 samples,
with concentrations higher than 6.25 having a significant anti-
growth effect on all samples. Compared to etoposide, the Pd
complex at the same concentration (25 mM) was found to
significantly reduce cell viability at least 5.6-fold in benign samples
(P = 0.029) and 10.66-fold in malignant samples (P =,0.001)
(median values used to calculate fold difference). Significantly, the
Pd complex had a less pronounced effect in high Gleason grade
(8/9) prostate cancer (Figure 3C). For the benign and Gleason 6/7
cancer cultures the average IC50 was 8.67 mM and 7.16 mM
respectively, while for the high Gleason grade cancers (8/9) the
IC50 was 60.39 mM (Table 4), indicating that these cultures are
more resistant, or less susceptible to the complex. Considering the
need for new drugs to treat high Gleason grade tumours that are
often radiorecurrent and hormone-resistant, this is a significant
observation regarding these samples, and one that could have been
missed if using only cell lines.
Effect of Pd Complex on Cancer Stem Cells from Primary
Epithelial Cultures
Prostate tumours are heterogeneous, and so the anti-growth
effects of the Pd complex specifically on benign and malignant
stem cells (SCs) were explored. SCs were isolated from primary
cultures derived from three benign and five prostate carcinoma
(Gl6/7) patient samples. In addition to SCs, TA cells, and CB cells
were also isolated. The SCs are a rare population of cells, and as
such the anti-growth effect was measured by the ATP assay, since
it significantly more sensitive than the MTS assay and can
accurately measure low cell numbers (Figure 4A). The Pd complex
was tested at two different doses (6.25 and 25 mM) on the basis of
previous experiments where 6.25 mM was the lowest concentra-
tion inducing a significant anti-growth effect and 25 mM caused a
dramatic reduction in cell viability (80%–100% in BPH and
Gleason 6/7 cancers). It is clearly shown that 25 mM Pd complex
was significantly more cytotoxic in stem cells, compared to 25 mM
etoposide (Figure 4B). (Using a Wilcoxon rank sum test to measure
the effect of 25 mM etoposide versus 25 mM PD003, the latter is
significantly more cytotoxic with a P value = 0.004 in all three
tests, comparing each population separately). The 6.25 mM Pd
complex resulted in an anti-growth effect that was less than 25 mM
Pd complex but still more cytotoxic than 25 mM etoposide. (Using
a Wilcoxon rank sum test to compare 6.25 mM Pd complex versus
25 mM Pd, there is a significant difference in cytoxicity with a P
value =,0.001 in all three tests, comparing each population
separately). Cisplatin also appeared to be significantly cytotoxic to
all cell populations; 6 mM of cisplatin was equivalently cytotoxic to
6 mM Pd complex (P values showed no significant difference
SC‘v’SC=0.073, TA‘v’TA=0.4, CB‘v’CB= 0.533). SCs ap-
peared to have increased viability compared to TA and CB cells
following etoposide treatment (although this was not statistically
significant), which was not the case following Pd complex
treatment.
DNA-damaging Effect of Pd Complex
Since the mechanism of action of the Pd complex has not been
fully characterized, the DNA-damaging effect was assessed. 10,000
cells per well in 8-well chamber slides were treated for 48 h with
Pd complex. Nuclei with evidence of cH2AX nuclear foci,
indicative of DNA damage, were counted on 10 randomly chosen
fields at the highest (63x) magnification and the mean number of
positively-stained nuclei was calculated. At least 100 cells per well
were counted. Both etoposide and Pd complex at the same dose
yielded similar levels of DNA damage (Figure 5A). 3.12 mM of the
Pd complex did not induce a significant level of DNA damage.
Effect of Pd Complex on the Cell Cycle
Following on from the observation that the Pd complex caused
DNA damage, we explored its effect on cell cycle status, since
DNA damage can lead to activation of cell cycle checkpoints and
cell death (Figure 5B–C, Supplementary Figure S3). Etoposide
caused an S phase arrest in PNT2-C2, PC3 and LNCaP cell lines
and also in primary prostate epithelial cells (measured at 48 h post-
treatment), which is not unexpected since etoposide treatment
leads to DNA damage in the S phase of the cell cycle [27].
Following treatment with the Pd complex, the cell lines showed an
increase in cells with sub-G1 DNA content, indicative of cell death
in all cases, except PC3 cells where there was almost no change.
Of the other cell lines, the PNT2-C2 cells were the least
susceptible. Generally, at lower concentrations (6 mM and
12 mM), the Pd complex showed similar levels of cell death to
the cisplatin and etoposide controls. In the normal cells (BPH-1,
PNT2-C2), the increase in cells with sub-G1 DNA content was
accompanied by a reduction in the S and G2 peaks, indicative of
either a G1 arrest followed by cell death, or a cell replication
failure preceding cell death. In primary cells, treatment with the
Pd complex gave a clear dose response showing increase in sub-G1
Table 4. IC50 values of the Pd complex in primary cells.
BPH primary cells IC50 (mM) New
7611 6.974
1608 5.969
3108 7.326
8109 14.43
AVERAGE 8.67475
PCa Primary cells (Gl7) IC50 (mM) New
06411ra 3.778
22412 6.303
06411lb 5.196
07011la 5.357
07011lb 6.025
07311ra 5.371
06211rb 11.06
06711rb 8.241
06611lb 13.12
AVERAGE 7.16122
PCa Primary cells (Gl8/9) IC50 (mM)
16312 70.41
22912 46.68
14912 64.07
AVERAGE 60.38666667
doi:10.1371/journal.pone.0064278.t004
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content, and also induced an increase in cells with more than 4N
DNA content, potentially indicative of induction of aneuploidy.
Similarly to etoposide, cisplatin caused an S phase arrest in PNT2-
C2 cells, LNCaPs and PC3 cells as well as primary cells. Overall, it
appears that the Pd complex had a different effect on the cell cycle
status than either etoposide or cisplatin.
Figure 2. Anti-growth effect of the Pd complex on cell lines. Anti-growth effect was measured by the MTS assay at 24 h, 48 h and 72 h.
PNT1A, PNT2-C2, and BPH-1 have either normal tissue or benign prostatic hyperplasia tissue origin (Ai–iii), while PC-3, LNCaP and P4E6 cell lines have
malignant origin (Bi–iii). IC50s are presented in Table 3. Transformed graphs are presented in Supplementary Figure S1.
doi:10.1371/journal.pone.0064278.g002
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Figure 3. Anti-growth effect of the Pd complex on primary cultures. Anti-growth effect was measured by the MTS assay at 72 h using cells
derived from patients with (A) benign prostate hyperplasia, (B) prostate carcinoma with Gleason grade 6/7 and (C) prostate carcinoma with Gleason
grade 8/9. IC50s are presented in Table 4. Transformed graphs are presented in Supplementary Figure S2.
doi:10.1371/journal.pone.0064278.g003
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Figure 4. Anti-growth effect of the Pd complex on cancer stem cells (CSC). (A) MTS assay and ATP assay were compared to assess anti-
growth effect using small cells numbers. (B) Anti-growth effect was measured by the ATP assay using SCs, TA cells and CB cells derived from three
patients with benign prostate hyperplasia (white-filled shapes) and five patients with prostate carcinoma (black-filled shapes). White bar represents
the median value of all the samples.
doi:10.1371/journal.pone.0064278.g004
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Figure 5. DNA-damaging effect and effect on Cell Cycle Status of Pd complex. (A) Primary cultures isolated from two patients with prostate
carcinoma were assessed. Cells were stained and scored for nuclear foci indicative of DNA damage Representative examples of cells negative and
positive for nuclear foci are shown. (B) Normal (PNT2-C2) and benign (BPH-1) cell lines, three cancer cell lines (P4E6, PC-3 and LNCaP) and (C) four
primary cultures derived from patients with prostate carcinoma were treated with three concentrations of palladium complex or etoposide or
cisplatin as control treatments. Cell cycle phase was measured using propidium iodide staining and flow cytometry analysis.
doi:10.1371/journal.pone.0064278.g005
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Induction of Apoptosis and Autophagy by the Pd
Complex
The indication of reduced cell growth resulting from the cell
proliferation assays, along with the increase in sub-G1 content of
the treated cell populations, led to the investigation of cleaved
caspase-3 activity to assess induction of apoptosis (Figure 6A(i),
Supplementary Figure S3). There was a clear induction of cleaved
caspase-3 in BPH-1, PNT2-C2 and P4E6 cells when treated with
Pd complex, etoposide and cisplatin. However induction of
cleaved caspase-3 in LNCaP cells was only observed after
treatment with 25 mM Pd complex, and there was no evidence
of cleaved caspase-3 in PC3 cells that present as a very resistant
cell line. This also correlated with the much lower percentage of
PC3 cells with a sub-G1 DNA content. More significantly, there
was no evidence of cleaved caspase-3 in two primary samples
(Figure 6B(i)), and only a positive result with the BPH sample at a
low dose. Since the sub-G1 content increases in primary cells in
response to Pd complex but with no corresponding caspase
activity, this may mean that the apoptotic kinetics differ between
the primary cells and cell lines or that the sub-G1 content in the
primary cells could be attributed to necrosis. To investigate the
mechanism of death in the cell lines and indeed the absence of
apoptosis in the primary cells, levels of LC3-I and LC3-II were
measured, to assess autophagy. The ratio of LC3-II to LC3-1 used
to be the standard measurement of autophagy, however it is now
accepted that levels of LC3-II alone should be assessed relative to a
typical control such as actin [28,29]. There was a clear increase in
the expression of LC3-II in BPH-1, PNT2-C2 and P4E6 cells
following increasing doses of Pd complex (Figure 6A(ii). Treatment
with etoposide or cisplatin did not significantly change levels of
LC3-I and LC3-II. The levels of LC3-I and LC3-II in LNCaP and
PC3 cells did not change dramatically or in a dose-dependent
fashion with any treatment. In all primary cells there was a clear
increase in LC3-II, the modified version of LC3-I that is present
on the autophagosomes and indicative of autophagy [29], with
increasing Pd complex treatment (Figure 6B(ii)). This was also
observed using immunofluorescence and autophagosomes were
observed in primary cells following treatment with Pd complex
(Figure 6C). Again, there was no significant change in LC3-I or
LC3-II levels following etoposide or cisplatin treatment. This
provided further clear evidence that the mechanism of action of
the Pd complex is different to etoposide or cisplatin, and indeed
different between the cell types studied.
Discussion
Recurrent prostate cancer eventually results in the death of the
patient due to resistance to chemotherapy and ineffective
chemotherapy, almost inevitably within 2 years from the failure
of hormone treatment [4]. Therefore, more efficient drugs/
approaches are required. In this study, we investigated the anti-
growth effect of a novel palladium complex, which is a growing
area in anti-cancer drug development. In vitro studies on different
kinds of palladium complexes recently synthesized by both our
group and others have produced promising results [19,20,30]. In
addition to in vitro studies, our in vivo study on breast cancer cell
lines also resulted in considerable cell death by inducing apoptosis
via cell death receptors, as well as inhibition of angiogenesis [25].
In this study, we have found that the Pd complex had a
significant growth-inhibiting activity against both prostate cancer
cell lines and cell lines derived from normal and benign prostate.
IC50 values have ranged from 0.1064 mM to 26.79 mM (72 h),
depending on the cell line. In the literature, IC50 values of
palladium compounds also have a broad range. In the study of
Nadeem et al [18] it varied from 5.80 to .100 mM. The reason
for this broad range may be related to the nature of ligands
attached to the palladium metal core. In another study, in which
different cell lines from different cancer types (central nervous
system, colon, breast, leukemia, and prostate) were used, the Pd
complexes resulted in broad range (13 to.100 mM) of IC50 values
depending on both cell types and the mono- and dinuclear Pd
complexes [31]. Taken together, the great variability in IC50
values seems to depend on both cell type and the ligand attached.
In the study of Mukherjee et al using palladium complexes,
prostate cancer (PC-3) cells died by apoptosis following cell cycle
arrest at G2/M phase [20]. Ultimately, it would be hoped that a
new drug preferentially killed cancer cells over normal cells.
Although it was first encouraging that one of the normal cell lines,
PNT2-C2, appeared to be less susceptible to the Pd complex than
the other normal (PNT1A) and benign (BPH-1) cell lines, once
compared to the cancer cell lines it became apparent that the
cancer cell lines are overall less susceptible to the Pd complex with
average IC50 values at 72 h being 11.53 mM, whereas the normal
cell lines had an average of 0.38 mM. Therefore, more drug is
required to reduce viability of the cancer cells. This is disappoint-
ing but unfortunately not surprising, and new approaches to
modify the compound in order to target it to the tumour while
sparing the normal tissue would be desirable. Significantly, this
study shows the importance of using a panel of cell lines, and not
just one ‘normal’ and one ‘cancer’ cell line. There is variability
between the normal versus cancers, just as there is variability
between the different normal cell lines and different cancer cell
lines.
Cell lines are very commonly used for initial high throughput
screening of cytotoxic anti-cancer compounds. However, it is
physiologically more relevant to use primary cultures to obtain
results that are closer to the patient. Therefore, in addition to the
many cell lines used in this study, we studied the anti-growth effect
of the Pd complex on primary cultures from patient tumour
samples (Gleason grade 7). We found that the Pd complex had a
powerful growth-inhibiting effect on these primary cancer cells.
Most of the IC50 values had quite a narrow range of around 3.778
to 13.12 mM depending on the patient from whom the cells were
isolated. This was comparable to the cancer cell line IC50 values.
Interestingly, when the Pd complex was tested against the cells
isolated from benign prostatic hyperplasia patients the results were
quite similar to those found in the malignant samples with IC50
values ranging from 5.969 mM to 14.43 mM. Therefore, once
again the Pd complex did not preferentially kill cancer cells, but
importantly did not preferentially kill benign primary cells (unlike
the normal cell lines). However, more significantly, when the drug
was tested against cultures from high Gleason grade tumours
(Gleason 8/9) the IC50 range for these samples was 46.68–
70.41 mM. Therefore, around ten times higher concentration of
the drug is required (using median values) to reduce the viability of
these aggressive cancers compared to the lower grade cancers.
This is a statistically significant difference, P= 0.016. This is the
first study testing this novel compound on primary epithelial cell
cultures of prostate and clearly highlights the utility of both cell
lines and primary cells when assessing a new drug.
There is now increasing evidence that cancer stem cells are
responsible for the recurrence of disease, due to their resistance to
current chemotherapy [32,33,34]. Therefore, we investigated the
effect of the Pd complex on cancer stem cells isolated from
malignant samples and stem cells isolated from benign prostate
hyperplasia samples. In addition to CSCs, TA and CB cells from
the same cultures were also isolated and studied. We found that
the Pd complex had much more potent cytotoxic activity than
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etoposide at the same concentration (25 mM) but had comparable
toxicity to cisplatin at the 6 mM range. This is also the first report
in the literature, to our knowledge, on the effect of Pd complexes
on cancer stem cells. Eradication of cancer stem cells is an aim of
most novel strategies, but with the potential for these cells to
display increased resistance, it is likely that they may need more
rigorous treatment. In fact, in our study we also used the
concentration of 50 mM of the complex, which killed all cells (data
not shown). However, this concentration may be too toxic to the
other cells of the body, and thus not be tolerated by patients.
Indeed, although we observed significant anti-growth effects of
cancer cells, this Pd complex also efficiently killed normal and
benign cells. The overall toxicity of the drug will be an important
future consideration.
To investigate the mechanism of cell death and the effect of the
Pd complex on the cell cycle, we first studied the DNA-damaging
effect of the Pd complex. Platinum compounds are known to
induce DNA adducts, which block replication and transcription
resulting in DNA damage and cell death [35]. Interestingly, we
found that both Pd complex and etoposide caused the same level
of DNA damage, measured as cH2AX foci (indicative of double-
strand breaks) although the Pd complex resulted in a more
powerful cytotoxic effect than etoposide. This implies that some of
the DNA damage resulting from etoposide treatment may be
repairable, but the damage caused by the Pd complex may not,
and is therefore more lethal. Future studies will develop this area
and will investigate the types of DNA damage occurring as well as
the active DNA repair mechanisms. It is known that there can be
resistance to platinum-based drugs and that this can be related to
the DNA repair mechanisms in the cell [35]. It will therefore be
interesting to determine if cells also acquire resistance to palladium
complexes, and whether this is through similar mechanisms, or
indeed if they are less likely to acquire resistance to these
compounds. Following increase of the sub-G1 population in the
cell cycle analysis, induction of apoptosis was confirmed with
Western blotting of cleaved caspase-3. Interestingly apoptosis was
induced in all of the cell lines (only at the highest Pd complex
concentration for LNCaP), except PC3. No apoptosis was induced
in the primary cancer cells.
In both cell lines and primary cells, autophagy was measured by
assessing levels of LC3-I and LC3-II. Increased levels of LC3-II
protein typically hints at induction of autophagy, although future
studies would have to incorporate autophagic flux to elucidate the
complete response [28,36]. Increased levels of LC3-I may occur
prior to an increase in LC3-II or could indicate that there is a
block in autophagy at an early stage. Autophagy is a dichotomy in
cancer because in some circumstances it can be a cell-protective
survival mechanism responding to hypoxia, nutrient deprivation
Figure 6. Expression of apoptosis and autophagy-related proteins following treatment with Pd complex. Normal (PNT2-C2) and benign
(BPH-1) cell lines, three cancer cell lines (P4E6, PC-3 and LNCaP) (A) and four primary cultures (B) one derived from patient with BPH and three derived
from patients with prostate carcinoma were treated with three concentrations of palladium complex or etoposide or cisplatin as control treatments.
Lysates were harvested and Western blotting was carried out staining for cleaved caspase-3 indicative of apoptosis induction or LC3B protein,
indicative of autophagy. (C) Images of primary cells (sample 23912) treated with Pd complex and stained with LC3-B antibody. Shown are three
example images of untreated cells and cells treated with 12 mM and 25 mM Pd complex. Autophagosome vesicles are clearly visible in red.
doi:10.1371/journal.pone.0064278.g006
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or stress, whilst in other circumstances it can be a prelude to
autophagy-induced caspase-independent cell death [37,38]. In-
deed, autophagy and apoptosis are activated by similar stimuli but
can be mutually exclusive or simultaneous [37]. In terms of using
autophagy as a treatment strategy in cancer, this has been
approached in two ways. In CML, the combination of a TK
inhibitor with an autophagy inhibitor increased cytotoxicity
[39,40]. Secondly, use of temolozide, a pro-autophagic drug, in
glioblastoma in combination with an mTOR inhibitor induced
autophagy and cell death [41]. Therefore, it is imperative to
understand the biology of the cancer cells under treatment before
deciding on the best strategy. Indeed, within this dichotomous
role, it seems that autophagy is less active in early stage cancers
with its cell-protective role, only coming to the fore in later stage
cancers [41,42,43]. In terms of prostate cancer, there have already
been studies indicating that autophagy protects against hormone
ablation therapy, and combining androgen deprivation with
autophagy inhibition led to synergistic cell death suggesting a
new potential strategy to overcome hormone therapy resistance
[44]. There are also clinical trials underway combining docetaxel
(standard chemotherapy for prostate cancer) with hydroxyquinone
autophagy inhibitor [45]. From our results, the presence or
absence of PTEN may contribute to the outcome of these
strategies. In PC3 and LNCaP cells the palladium compound did
not induce autophagy and only induced apoptosis at high
concentrations (LNCaP) or not at all. Both cell lines contain
inactive PTEN [46] and since mTOR is a key negative regulator
of autophagy, the absence of PTEN, a negative regulator of
mTOR, could result in lack of induction of autophagy. In prostate
cancers around 40% of patients lack PTEN activity, a proportion
that increases in castration-resistant prostate cancer [47,48]. The
other cell lines tested (BPH-1, PNT2-C2 and P4E6) are PTEN-
positive and were susceptible to the drug. Thus, there may be
differential efficacy of this combination strategy between patients,
depending on the genetic background of the tumour.
In conclusion, the Pd complex had a considerable anti-growth
effect on most prostate cancer cell lines and primary cultures.
Importantly, it also successfully inhibited the viability of cancer
stem cells, implying that this Pd complex may be used for the
treatment of metastatic prostate cancer that is extremely resistant
to conventional therapy. Previous work has shown that Palladium
complexes can cause cell death by necrosis or apoptosis. This study
showed that the Pd complex induced autophagy in some cases,
and therefore points to a new area of investigation. Here we
present a comprehensive overview of the effects of a novel
Palladium complex on cell viability in an extended panel of cell
lines and primary cells, including cancer stem cells, and provide
first indications of a complex cell death mechanism. Although we
have shown that this is a drug with high toxicity, the potential to
use it at lower doses in a combination strategy with autophagy
modulators, is worth further exploration. Finally, we think that a
key message of this study lies in the use of a panel of cell lines
alongside patient samples. We have shown that depending on the
genetic background of the cells as well as the aggressiveness of the
cancer, there are different outcomes to drug treatment. This
should be taken into account when testing other palladium drugs
and drugs in general, such that one cell line is not overly relied
upon, and that patient samples are included in any study of this
kind.
Supporting Information
Figure S1 Graphs of transformed data from Figure 2 following
application of the nonlinear regression (curve fit) that represents
the log(inhibitor) ‘v’ normalized response, from which the IC50s
were calculated (GraphPad Prism software).
(TIF)
Figure S2 Graphs of transformed data from Figure 3 following
application of the nonlinear regression (curve fit) that represents
the log(inhibitor) ‘v’ normalized response, from which the IC50s
were calculated (GraphPad Prism software).
(TIF)
Figure S3 Images of cells treated for flow cytometry cell cycle
analysis and for protein lysates.
(TIF)
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